SNGX
HealthcareSoligenix, Inc.
Biotechnology
$0.33+4.06%
Key events (≥5% daily moves)
Up dayDown day
About This Company
Soligenix is a biotechnology company focused on creating treatments for rare diseases, especially those with few options. They are developing several potential medicines, including a light-based therapy for a type of skin cancer and treatments for inflammatory conditions. Additionally, they are working on vaccines and therapies for public health threats, like ricin poisoning and antibiotic-resistant infections.
https://www.soligenix.comKey Statistics
Open$0.32
Day High$0.34
Day Low$0.31
Prev. Close$0.32
52-Week High$6.23
52-Week Low$0.31
Market Cap$3.41M
Volume872.72K
Avg. Volume—
P/E Ratio—
EPS—
Beta1.31
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
14
Country
US
IPO Date
1994-04-04
Exchange
NASDAQ
52-Week Range
$0.31
52W Low
$0.33
Current
$6.23
52W High
Catalysts & Risks
Catalysts
- ▲Positive Phase 3 clinical trial results or regulatory approval for HyBryte (SGX301) in Cutaneous T-cell Lymphoma (CTCL)
- ▲Successful advancement of SGX942 (dusquetide) through clinical trials for oral mucositis or other indications
- ▲Strategic partnerships, licensing agreements, or non-dilutive funding for pipeline assets
- ▲Positive data and potential regulatory progress for their biodefense programs (e.g., RiVax, ThermoVax)
Risks
- ▼Failure to achieve positive clinical trial results or regulatory approval for key drug candidates
- ▼Inability to secure sufficient funding for ongoing clinical trials and operations, leading to dilution or delays
- ▼Intense competition from larger pharmaceutical companies with more resources
- ▼Potential for intellectual property challenges or expiration of patent protection for their drug candidates
AI-generated · For informational use only